ROR1 is also required to sustain the association between EGFR and receptor tyrosine-protein kinase erbB-3 (ERBB3), the activation of ERBB3, consequentially, making ROR1 an ideal target for therapies against EGFR-TKI resistance in lung adenocarcinoma (29). This evidence concerns the gene ROR1 and lung adenocarcinoma.